# Lipoprotein lipase
**Lipoprotein lipase** (LPL) is an extracellular enzyme anchored to the luminal surface of capillary endothelium that hydrolyzes the triglycerides carried in circulating chylomicrons and very low-density lipoproteins (VLDL), releasing fatty acids for tissue uptake and generating remnant lipoproteins that the liver clears.[1](https://www.ncbi.nlm.nih.gov/books/NBK537040/) It is the major enzyme regulating plasma triglyceride levels in humans and many other species, and its deficiency causes familial chylomicronemia syndrome (FCS), formerly called Frederickson type 1 hyperlipoproteinemia.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/)
| Key fact | Detail |
|---|---|
| Location | Bound to capillary endothelium in adipose tissue, skeletal muscle, and heart; absent from the liver, which uses hepatic lipase instead[1](https://www.ncbi.nlm.nih.gov/books/NBK537040/) |
| Reaction | Hydrolyzes triglycerides in chylomicrons and VLDL to two free fatty acids and one 2-monoacylglycerol molecule[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) |
| Protein size | After cleavage of a 27 amino acid signal peptide, mature LPL is 448 amino acids, about 55 kDa[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) |
| Essential cofactors | Apo C-II and apo A-V activate LPL; apo C-III and apo C-I inhibit it[3](https://ncbi.nlm.nih.gov/books/NBK305896/?report=classic) |
| Endogenous inhibitors | ANGPTL3, ANGPTL4, and ANGPTL8 inhibit LPL activity; ANGPTL8 acts only in complex with ANGPTL3 or ANGPTL4[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) |
| Deficiency disease | Biallelic loss-of-function variants in LPL cause about 80% of familial chylomicronemia syndrome cases[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) |
| Discovery | Lipolytic activity observed by Paul Hahn in 1943; the heparin-induced clearing factor was isolated and named LPL by Edward Korn in 1955[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) |
## Function in lipid metabolism
LPL is synthesized by the parenchymal cells of adipose tissue, skeletal muscle, and cardiac muscle, secreted, and captured on the capillary endothelium by GPIHBP1 (glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1), which shuttles the enzyme from the interstitial space to the vascular lumen.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) There it binds triglyceride-rich lipoproteins and hydrolyzes their triglyceride core. Chylomicrons, which are about 90% triglyceride, are converted into chylomicron remnants, and VLDL is converted into intermediate-density lipoprotein (IDL); the liver takes up the remnants, and hepatic lipase further processes IDL into LDL.[3](https://ncbi.nlm.nih.gov/books/NBK305896/?report=classic) • [4](https://academic.oup.com/jcem/article/111/3/845/8407532)
The liberated fatty acids are stored as triglyceride in adipose tissue or oxidized for energy in skeletal and cardiac muscle.[1](https://www.ncbi.nlm.nih.gov/books/NBK537040/) LPL also has non-catalytic roles: it mediates cellular uptake of LDL, HDL-associated cholesteryl esters, and remnant particles by interacting with the LDL receptor, cell-surface proteoglycans, and LRP1.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/)
## Structure and cofactors
LPL belongs to the mammalian triacylglycerol lipase gene family, which also includes pancreatic lipase, hepatic lipase, and endothelial lipase.[5](https://www.ahajournals.org/doi/pdf/10.1161/hq0102.101551) The enzyme has two functional domains connected by a hinge: an N-terminal α/β-hydrolase domain spanning residues 28 to 340, containing a catalytic triad of Ser159, Asp183, and His268, and a C-terminal lipid-binding domain formed by a β-barrel.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) The catalytic hydrolase domain is inherently unstable and prone to spontaneous unfolding, so the crystal structure was solved for LPL bound to GPIHBP1 rather than for LPL alone; the intrinsically disordered acidic domain of GPIHBP1 stabilizes the catalytic domain.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) Whether LPL is active as a monomer or dimer has been debated; recent work supports a stable, functional monomer, and cryo-EM studies have shown the inactive form to be a polymer.[1](https://www.ncbi.nlm.nih.gov/books/NBK537040/) • [6](https://pmc.ncbi.nlm.nih.gov/articles/PMC8627828/)
Activation depends on apolipoproteins carried by the substrate particle itself. Apo C-II, an essential activator, binds and stabilizes the lid region covering the active site, opening it to substrate; apo A-V binds GPIHBP1 and enhances the association of lipoproteins with the endothelial surface.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) Apo C-III and apo C-I inhibit activity, apparently by preventing LPL from binding the lipid-water interface of the lipoprotein.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/)
## Regulation
LPL activity is tuned to nutritional state by the angiopoietin-like proteins ANGPTL3, ANGPTL4, and [ANGPTL8](https://www.edgepedia.org/angptl8), all inhibitors.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) In the fed state, insulin signaling induces hepatic and adipose ANGPTL8 expression, favoring the ANGPTL3/8 complex that suppresses LPL in oxidative tissues while the weaker ANGPTL4/8 complex permits adipose LPL activity, so dietary triglyceride is directed to storage. In the fasted state, reduced ANGPTL8 and increased apo A-V shift triglyceride delivery toward oxidative tissues.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/) Insulin also directly stimulates LPL expression, and LPL activity is reduced in poorly controlled diabetes, contributing to hypertriglyceridemia.[3](https://ncbi.nlm.nih.gov/books/NBK305896/?report=classic) Intracellularly, the chaperones LMF1 and [SEL1L](https://www.edgepedia.org/sel1l) on the endoplasmic reticulum membrane ensure proper folding and maturation of the nascent enzyme.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/)
## LPL deficiency and familial chylomicronemia syndrome
[Familial chylomicronemia syndrome](https://www.edgepedia.org/familial-chylomicronemia-syndrome) is a rare autosomal recessive disorder, affecting roughly 1 to 13 persons per million in the United States, in which reduced or absent LPL activity causes fasting triglycerides of 10 mmol/L (885 mg/dL) or more, chylomicronemia, eruptive xanthomas, lipemia retinalis, and a markedly increased risk of acute pancreatitis.[7](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219947Orig1s000RiskR.pdf) • [4](https://academic.oup.com/jcem/article/111/3/845/8407532) Biallelic loss-of-function variants in any of five genes of the LPL pathway can cause it: LPL itself (60 to 80% of cases), GPIHBP1 (10 to 15%), [APOA5](https://www.edgepedia.org/apoa5) (5 to 10%), APOC2 (1 to 5%), and LMF1 (1 to 2%).[4](https://academic.oup.com/jcem/article/111/3/845/8407532) Standard triglyceride-lowering drugs that require LPL activity, such as fibrates and omega-3 fatty acids, show minimal effect in FCS, and a restrictive low-fat diet has been the mainstay of therapy.[4](https://academic.oup.com/jcem/article/111/3/845/8407532) • [7](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219947Orig1s000RiskR.pdf)
Heterozygosity for the same LPL variants produces a highly variable triglyceride phenotype, ranging from normal levels to severe [hypertriglyceridemia](https://www.edgepedia.org/hypertriglyceridemia), with secondary factors such as obesity and diabetes modulating expression.[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/)
## Therapeutics targeting the LPL pathway
Because apo C-III both inhibits LPL and impairs clearance of triglyceride-rich lipoproteins, it became a drug target. The antisense oligonucleotide volanesorsen reduced apo C-III by 84% and triglycerides by up to 77% at 3 months in the phase 3 APPROACH trial in familial chylomicronemia syndrome, with thrombocytopenia and injection-site reactions as common adverse events; the European Union approved it for FCS in May 2019.[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC9449100/) Its GalNAc-conjugated successor olezarsen (Tryngolza) was approved by the FDA in December 2024 as the first product specifically for FCS in the United States.[7](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219947Orig1s000RiskR.pdf) Agents against ANGPTL3, including the monoclonal antibody evinacumab, which lowered triglycerides by 55.0% at week 24 in phase 3 testing, exploit the same pathway.[8](https://pmc.ncbi.nlm.nih.gov/articles/PMC9449100/)
[Gene therapy](https://www.edgepedia.org/gene-therapy) has also been attempted: alipogene tiparvovec (Glybera), an AAV-based gene replacement therapy, was approved in 2012 in Europe for LPL deficiency, the first EMA-approved AAV gene therapy, though host immune responses limit long-term expression.[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448413/)
## LPL and atherosclerosis
LPL also participates in atherogenesis. It is a component of atherosclerotic lesions derived from macrophages, and patients with advanced atherosclerosis show elevated LPL mass and activity in post-heparin plasma. By hydrolyzing triglycerides from chylomicrons and VLDL, LPL generates remnant particles rich in cholesterol esters that macrophages incorporate; macrophages also re-esterify the liberated fatty acids, accumulating cholesterol and transforming into foam cells.[1](https://www.ncbi.nlm.nih.gov/books/NBK537040/)
## References
1. [Pirahanchi Y, Anoruo M, Sharma S. Biochemistry, Lipoprotein Lipase. StatPearls, updated July 30, 2023.](https://www.ncbi.nlm.nih.gov/books/NBK537040/)
2. [Perera SD, Wang J, McIntyre AD, Hegele RA. Lipoprotein Lipase: Structure, Function, and Genetic Variation. Genes. 2025;16(1):55.](https://pmc.ncbi.nlm.nih.gov/articles/PMC11764694/)
3. [Introduction to Lipids and Lipoproteins. Endotext, NCBI Bookshelf.](https://ncbi.nlm.nih.gov/books/NBK305896/?report=classic)
4. [Hegele RA et al. Approach to the Adult Patient with Chylomicronemia. Journal of Clinical Endocrinology & Metabolism. 2026;111(3):845–859.](https://academic.oup.com/jcem/article/111/3/845/8407532)
5. [Lipoprotein Lipase in the Arterial Wall. Arteriosclerosis, Thrombosis, and Vascular Biology.](https://www.ahajournals.org/doi/pdf/10.1161/hq0102.101551)
6. [Lipoprotein Lipase and Its Regulators: An Unfolding Story. PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC8627828/)
7. [FDA Integrated/Risk Review for plozasiran NDA 219947 (FCS background, olezarsen approval).](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/219947Orig1s000RiskR.pdf)
8. [Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia. PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC9449100/)
9. [Gene therapy and genome editing for lipoprotein disorders. PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC12448413/)
---
*Topic: Encyclopedia › Life and health › Biological foundations › Biochemistry and metabolism › Metabolism and metabolic pathways › Lipid and fatty acid metabolism › Lipid metabolism enzyme families and activities › Lipases and lipid esterases*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026; Oct 21, 2026 · Edited: Oct 15, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license